U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Platinum-Sensitive Ovarian Carcinoma

MedGen UID:
1692268
•Concept ID:
C5204784
•
Neoplastic Process
Synonym: Platinum-Sensitive Ovarian Cancer

Definition

Ovarian carcinoma that has a documented response to platinum-based chemotherapy. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVPlatinum-Sensitive Ovarian Carcinoma

Professional guidelines

PubMed

Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature.
Ciccone MA, Maoz A, Casabar JK, Machida H, Mabuchi S, Matsuo K
Expert Opin Investig Drugs 2016 Jul;25(7):781-96. Epub 2016 May 13 doi: 10.1080/13543784.2016.1181748. PMID: 27101098Free PMC Article

Recent clinical studies

Etiology

The value of PET/CT for cytoreductive surgery selection in recurrent ovarian carcinoma.
Nunes RL, Teixeira FR, Diniz TP, Faloppa CC, Mantoan H, da Costa AABA, Baiocchi G
J Gynecol Oncol 2023 May;34(3):e31. Epub 2023 Jan 20 doi: 10.3802/jgo.2023.34.e31. PMID: 36731894Free PMC Article
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators
Lancet 2017 Oct 28;390(10106):1949-1961. Epub 2017 Sep 12 doi: 10.1016/S0140-6736(17)32440-6. PMID: 28916367Free PMC Article
Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: a pilot study.
Argenta PA, Sueblinvong T, Geller MA, Jonson AL, Downs LS Jr, Carson LF, Ivy JJ, Judson PL
Gynecol Oncol 2013 Apr;129(1):81-5. Epub 2013 Jan 23 doi: 10.1016/j.ygyno.2013.01.010. PMID: 23352917
A phase II trial of CI-958 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
Hoffman MA, Blessing JA, Nuñez ER
Gynecol Oncol 2001 Jun;81(3):433-5. doi: 10.1006/gyno.2001.6182. PMID: 11371134
Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
Rose PG, Blessing JA, Mayer AR, Homesley HD
J Clin Oncol 1998 Feb;16(2):405-10. doi: 10.1200/JCO.1998.16.2.405. PMID: 9469322

Diagnosis

Top advances of the year: Ovarian cancer.
Lumish MA, Kohn EC, Tew WP
Cancer 2024 Mar 15;130(6):837-845. Epub 2023 Dec 15 doi: 10.1002/cncr.35135. PMID: 38100616
The value of PET/CT for cytoreductive surgery selection in recurrent ovarian carcinoma.
Nunes RL, Teixeira FR, Diniz TP, Faloppa CC, Mantoan H, da Costa AABA, Baiocchi G
J Gynecol Oncol 2023 May;34(3):e31. Epub 2023 Jan 20 doi: 10.3802/jgo.2023.34.e31. PMID: 36731894Free PMC Article
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators
Lancet 2017 Oct 28;390(10106):1949-1961. Epub 2017 Sep 12 doi: 10.1016/S0140-6736(17)32440-6. PMID: 28916367Free PMC Article
Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: a pilot study.
Argenta PA, Sueblinvong T, Geller MA, Jonson AL, Downs LS Jr, Carson LF, Ivy JJ, Judson PL
Gynecol Oncol 2013 Apr;129(1):81-5. Epub 2013 Jan 23 doi: 10.1016/j.ygyno.2013.01.010. PMID: 23352917
Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
Rose PG, Blessing JA, Mayer AR, Homesley HD
J Clin Oncol 1998 Feb;16(2):405-10. doi: 10.1200/JCO.1998.16.2.405. PMID: 9469322

Therapy

Top advances of the year: Ovarian cancer.
Lumish MA, Kohn EC, Tew WP
Cancer 2024 Mar 15;130(6):837-845. Epub 2023 Dec 15 doi: 10.1002/cncr.35135. PMID: 38100616
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators
Lancet 2017 Oct 28;390(10106):1949-1961. Epub 2017 Sep 12 doi: 10.1016/S0140-6736(17)32440-6. PMID: 28916367Free PMC Article
Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: a pilot study.
Argenta PA, Sueblinvong T, Geller MA, Jonson AL, Downs LS Jr, Carson LF, Ivy JJ, Judson PL
Gynecol Oncol 2013 Apr;129(1):81-5. Epub 2013 Jan 23 doi: 10.1016/j.ygyno.2013.01.010. PMID: 23352917
Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study.
Miller DS, Blessing JA, Lentz SS, McMeekin DS
Cancer 2003 Oct 15;98(8):1664-9. doi: 10.1002/cncr.11690. PMID: 14534883
Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
Rose PG, Blessing JA, Mayer AR, Homesley HD
J Clin Oncol 1998 Feb;16(2):405-10. doi: 10.1200/JCO.1998.16.2.405. PMID: 9469322

Prognosis

The value of PET/CT for cytoreductive surgery selection in recurrent ovarian carcinoma.
Nunes RL, Teixeira FR, Diniz TP, Faloppa CC, Mantoan H, da Costa AABA, Baiocchi G
J Gynecol Oncol 2023 May;34(3):e31. Epub 2023 Jan 20 doi: 10.3802/jgo.2023.34.e31. PMID: 36731894Free PMC Article
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators
Lancet 2017 Oct 28;390(10106):1949-1961. Epub 2017 Sep 12 doi: 10.1016/S0140-6736(17)32440-6. PMID: 28916367Free PMC Article
Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study.
Miller DS, Blessing JA, Lentz SS, McMeekin DS
Cancer 2003 Oct 15;98(8):1664-9. doi: 10.1002/cncr.11690. PMID: 14534883

Clinical prediction guides

The value of PET/CT for cytoreductive surgery selection in recurrent ovarian carcinoma.
Nunes RL, Teixeira FR, Diniz TP, Faloppa CC, Mantoan H, da Costa AABA, Baiocchi G
J Gynecol Oncol 2023 May;34(3):e31. Epub 2023 Jan 20 doi: 10.3802/jgo.2023.34.e31. PMID: 36731894Free PMC Article
Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: a pilot study.
Argenta PA, Sueblinvong T, Geller MA, Jonson AL, Downs LS Jr, Carson LF, Ivy JJ, Judson PL
Gynecol Oncol 2013 Apr;129(1):81-5. Epub 2013 Jan 23 doi: 10.1016/j.ygyno.2013.01.010. PMID: 23352917
Mitochondrial ultrastructure-associated chemotherapy response in ovarian cancer.
Saitou M, Isonishi S, Hamada T, Kiyokawa T, Tachibana T, Ishikawa H, Yasuda M
Oncol Rep 2009 Jan;21(1):199-204. PMID: 19082462

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...